FR3054547B1 - Particules pseudo-virales et leurs utilisations - Google Patents

Particules pseudo-virales et leurs utilisations Download PDF

Info

Publication number
FR3054547B1
FR3054547B1 FR1657424A FR1657424A FR3054547B1 FR 3054547 B1 FR3054547 B1 FR 3054547B1 FR 1657424 A FR1657424 A FR 1657424A FR 1657424 A FR1657424 A FR 1657424A FR 3054547 B1 FR3054547 B1 FR 3054547B1
Authority
FR
France
Prior art keywords
pseudo
viral particles
relates
fusion protein
transmembrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1657424A
Other languages
English (en)
Other versions
FR3054547A1 (fr
Inventor
Veronique Gomord
Louis-Philippe Vezina
Loic Faye
Virginie CATALA
Anne-Catherine FITCHETTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANGANY GENETICS
Original Assignee
ANGANY GENETICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1657424A priority Critical patent/FR3054547B1/fr
Application filed by ANGANY GENETICS filed Critical ANGANY GENETICS
Priority to SG11201900383RA priority patent/SG11201900383RA/en
Priority to EP17767861.2A priority patent/EP3490597A1/fr
Priority to JP2019526380A priority patent/JP7461742B2/ja
Priority to AU2017303820A priority patent/AU2017303820B2/en
Priority to PCT/FR2017/052146 priority patent/WO2018020195A1/fr
Priority to BR112019001779-8A priority patent/BR112019001779A2/pt
Priority to CA3031294A priority patent/CA3031294A1/fr
Priority to US16/320,719 priority patent/US20190160167A1/en
Priority to KR1020197006155A priority patent/KR20190038600A/ko
Publication of FR3054547A1 publication Critical patent/FR3054547A1/fr
Application granted granted Critical
Publication of FR3054547B1 publication Critical patent/FR3054547B1/fr
Priority to JP2023206628A priority patent/JP2024028887A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La présente invention se rapporte à une protéine de fusion transmembranaire de type I ou II comprenant successivement a) optionnellement, un peptide signal ; b) une protéine ou un peptide d'intérêt ; c) un domaine coiled-coil ; et d) un domaine d'ancrage dans la membrane plasmique, constitué par un segment transmembranaire et un segment cytosolique. Elle est également relative aux particules pseudo-virales obtenues avec cette protéine de fusion.
FR1657424A 2016-07-29 2016-07-29 Particules pseudo-virales et leurs utilisations Active FR3054547B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1657424A FR3054547B1 (fr) 2016-07-29 2016-07-29 Particules pseudo-virales et leurs utilisations
US16/320,719 US20190160167A1 (en) 2016-07-29 2017-07-28 Pseudo-viral particles and uses of same
JP2019526380A JP7461742B2 (ja) 2016-07-29 2017-07-28 偽ウイルス粒子及びその使用
AU2017303820A AU2017303820B2 (en) 2016-07-29 2017-07-28 Pseudo-viral particles and uses of same
PCT/FR2017/052146 WO2018020195A1 (fr) 2016-07-29 2017-07-28 Particules pseudo-virales et leurs utilisations
BR112019001779-8A BR112019001779A2 (pt) 2016-07-29 2017-07-28 partículas semelhantes a vírus e usos das mesmas
SG11201900383RA SG11201900383RA (en) 2016-07-29 2017-07-28 Pseudo-viral particles and uses of same
EP17767861.2A EP3490597A1 (fr) 2016-07-29 2017-07-28 Particules pseudo-virales et leurs utilisations
KR1020197006155A KR20190038600A (ko) 2016-07-29 2017-07-28 바이러스 유사 입자 및 이의 용도
CA3031294A CA3031294A1 (fr) 2016-07-29 2017-07-28 Particules pseudo-virales et leurs utilisations
JP2023206628A JP2024028887A (ja) 2016-07-29 2023-12-07 偽ウイルス粒子及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1657424 2016-07-29
FR1657424A FR3054547B1 (fr) 2016-07-29 2016-07-29 Particules pseudo-virales et leurs utilisations

Publications (2)

Publication Number Publication Date
FR3054547A1 FR3054547A1 (fr) 2018-02-02
FR3054547B1 true FR3054547B1 (fr) 2020-06-05

Family

ID=57045182

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1657424A Active FR3054547B1 (fr) 2016-07-29 2016-07-29 Particules pseudo-virales et leurs utilisations

Country Status (10)

Country Link
US (1) US20190160167A1 (fr)
EP (1) EP3490597A1 (fr)
JP (2) JP7461742B2 (fr)
KR (1) KR20190038600A (fr)
AU (1) AU2017303820B2 (fr)
BR (1) BR112019001779A2 (fr)
CA (1) CA3031294A1 (fr)
FR (1) FR3054547B1 (fr)
SG (1) SG11201900383RA (fr)
WO (1) WO2018020195A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246041A2 (fr) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions et procédés pour un affichage de surface multivalent sur des particules enveloppées
TW202313668A (zh) * 2021-05-20 2023-04-01 美商阿徹羅伊斯生物製藥公司 免疫檢查點多價粒子組合物及其使用方法
TW202345912A (zh) * 2022-03-11 2023-12-01 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2023215699A1 (fr) * 2022-05-04 2023-11-09 Achelois Biopharma, Inc. Affichage multivalent sur des particules enveloppées avec des domaines d'oligomérisation humains

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1255510A (fr) 1960-01-28 1961-03-10 S E B A M Charnière invisible pour porte de meuble
CN101141979B (zh) 2005-03-18 2013-05-08 赛托斯生物技术公司 猫变应原融合蛋白及其用途
EP2044224A4 (fr) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Particules de type virus chimérique
JP5568702B2 (ja) 2006-11-08 2014-08-13 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック（セーエヌエルエス） 組換えポリペプチドの発現および翻訳後修飾の制御を標的化するための配列を有するポリペプチド
DK2610345T3 (en) 2007-11-27 2015-12-07 Medicago Inc RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ
US20120052082A1 (en) * 2010-04-09 2012-03-01 Zetra Biologicals, LLC Cross-protective influenza vaccine
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
FR2991996B1 (fr) * 2012-06-13 2016-07-08 Angany Genetics Methode de production d'allergenes recombinants de haute qualite par expression transitoire chez nicotiana benthamiana
EP2914283B1 (fr) * 2012-11-05 2020-05-20 Georgia State University Research Foundation, Inc. Vaccin universel contre la grippe à base de protéines m2e multiples hétérologues
EP2978848B1 (fr) 2013-03-28 2020-05-06 Medicago Inc. Production de particules de type viral de la grippe dans des plantes

Also Published As

Publication number Publication date
WO2018020195A1 (fr) 2018-02-01
FR3054547A1 (fr) 2018-02-02
AU2017303820B2 (en) 2022-10-20
KR20190038600A (ko) 2019-04-08
AU2017303820A1 (en) 2019-02-07
JP2019531760A (ja) 2019-11-07
JP7461742B2 (ja) 2024-04-04
JP2024028887A (ja) 2024-03-05
CA3031294A1 (fr) 2018-02-01
EP3490597A1 (fr) 2019-06-05
BR112019001779A2 (pt) 2019-05-07
US20190160167A1 (en) 2019-05-30
SG11201900383RA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
FR3054547B1 (fr) Particules pseudo-virales et leurs utilisations
AU2018351050A8 (en) Compositions and methods for selective protein degradation
MX2020010061A (es) Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
MA40138A1 (fr) Polypeptide présentant une activité de dégradation de polyester et utilisations de celui-ci
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EP3403082A4 (fr) Systèmes et procédés d'électrophorèse capillaire, point isoélectrique et analyse de poids moléculaire
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
ATE472334T1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
EP4019044A3 (fr) Protéines de fusion virales stabilisées de classe i
TN2017000020A1 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2020007628A (es) Composiciones y metodos de uso.
WO2018115017A3 (fr) Structure cristalline de gremlin-1 et anticorps inhibiteur
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
FR3094180B1 (fr) Composition proteique de feverole
WO2017079369A3 (fr) Nouveaux anticorps
FR3058159B1 (fr) Variants de polypeptide fc presentant une demi-vie augmentee
EA201991768A1 (ru) Слитые белки на основе фактора ix и способы их получения и пути применения
AU2017305946A8 (en) C1q and HMGB1 fusion proteins and uses thereof
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180202

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8